Clinical Outcomes of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) and Glucagon-Like Peptide-1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (GLP-1/GIP RA) Exposures Presenting to the Emergency Department.

Gartner HT, Simmons RE, Wan HZ, Sollee DR, Sheikh S

The Annals of pharmacotherapy23 Apr 2025Cited by 1 (Europe PMC)

PMID40269635DOI10.1177/10600280251334642PepBankPUB-40269635

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

1 result from studies that gave the peptide. 1 result from people.

01HumanObservational studySafety outcome
Among patients with receptor agonist exposures, semaglutide exposure was more prevalent in symptomatic than asymptomatic patients.
In plain wordsSemaglutide exposure was linked to greater representation among patients with symptoms than patients without symptoms.
Peptide
Semaglutide
Outcome
IncreaseSemaglutide exposure in symptomatic versus asymptomatic groups
Study
n = 152
Comparator
Asymptomatic patients
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Notably, a higher proportion of patients in the asymptomatic group were exposed to dulaglutide, and a higher proportion of patients in the symptomatic group were exposed to semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study of patients exposed to a GLP-1 or GLP-1/GIP RA across 3 poison centers between 2005 and 2023.
Summary · context
ToxSentryWeb identified 186 potential cases; 152 met the study criteria (130 symptomatic and 22 asymptomatic patients).
Report a problemFND-4026963514

Studies that did not test the peptide alone13

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

02HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
After pooled GLP-1 or GLP-1/GIP agonist exposures including dulaglutide, hypoglycemia occurred in 9% of patients.
In plain wordsAfter pooled drug exposures including dulaglutide, 9% of patients had low blood sugar.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableHypoglycemia after pooled receptor agonist exposures
Study
n = 152
Outcome group
Adverse events · Metabolic and weight
Measurements
Hypoglycemia
9%
pooled exposures
Source sentences
Summary
Hypoglycemia occurred in 9% of patients.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study of patients exposed to a GLP-1 or GLP-1/GIP RA across 3 poison centers between 2005 and 2023.
Summary · context
ToxSentryWeb identified 186 potential cases; 152 met the study criteria (130 symptomatic and 22 asymptomatic patients).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4026963505
03HumanNot a test of Semaglutide aloneObservational studySafety outcome
After pooled GLP-1 or GLP-1/GIP agonist exposures including semaglutide, hypoglycemia occurred in 9% of patients.
In plain wordsAfter pooled drug exposures including semaglutide, 9% of patients had low blood sugar.
Peptide
Semaglutide
Outcome
Not applicableHypoglycemia after pooled receptor agonist exposures
Study
n = 152
Outcome group
Adverse events · Metabolic and weight
Measurements
Hypoglycemia
9%
pooled exposures
Source sentences
Summary
Hypoglycemia occurred in 9% of patients.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study of patients exposed to a GLP-1 or GLP-1/GIP RA across 3 poison centers between 2005 and 2023.
Summary · context
ToxSentryWeb identified 186 potential cases; 152 met the study criteria (130 symptomatic and 22 asymptomatic patients).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4026963506
04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
Among patients with receptor agonist exposures, dulaglutide exposure was more prevalent in asymptomatic than symptomatic patients.
In plain wordsDulaglutide exposure was linked to greater representation among patients without symptoms than patients with symptoms.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseDulaglutide exposure in asymptomatic versus symptomatic groups
Study
n = 152
Comparator
Symptomatic patients
Outcome group
Adverse events · Whole body
Source sentences
Summary
Notably, a higher proportion of patients in the asymptomatic group were exposed to dulaglutide, and a higher proportion of patients in the symptomatic group were exposed to semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study of patients exposed to a GLP-1 or GLP-1/GIP RA across 3 poison centers between 2005 and 2023.
Summary · context
ToxSentryWeb identified 186 potential cases; 152 met the study criteria (130 symptomatic and 22 asymptomatic patients).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4026963513
05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
Among symptomatic patients after pooled GLP-1 or GLP-1/GIP agonist exposures including dulaglutide, nausea occurred in 92%.
In plain wordsAfter pooled drug exposures including dulaglutide, 92% of symptomatic patients had nausea.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableNausea after pooled receptor agonist exposures
Study
n = 130
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Nausea
92%
symptomatic patients; pooled exposures
Source sentences
Summary
Nausea (92%) and vomiting (76%) were the most reported clinical effects in the symptomatic group.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study of patients exposed to a GLP-1 or GLP-1/GIP RA across 3 poison centers between 2005 and 2023.
Summary · context
ToxSentryWeb identified 186 potential cases; 152 met the study criteria (130 symptomatic and 22 asymptomatic patients).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4026963501
06HumanNot a test of Semaglutide aloneObservational studySafety outcome
Among symptomatic patients after pooled GLP-1 or GLP-1/GIP agonist exposures including semaglutide, nausea occurred in 92%.
In plain wordsAfter pooled drug exposures including semaglutide, 92% of symptomatic patients had nausea.
Peptide
Semaglutide
Outcome
Not applicableNausea after pooled receptor agonist exposures
Study
n = 130
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Nausea
92%
symptomatic patients; pooled exposures
Source sentences
Summary
Nausea (92%) and vomiting (76%) were the most reported clinical effects in the symptomatic group.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study of patients exposed to a GLP-1 or GLP-1/GIP RA across 3 poison centers between 2005 and 2023.
Summary · context
ToxSentryWeb identified 186 potential cases; 152 met the study criteria (130 symptomatic and 22 asymptomatic patients).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4026963502
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
Among symptomatic patients after pooled GLP-1 or GLP-1/GIP agonist exposures including dulaglutide, vomiting occurred in 76%.
In plain wordsAfter pooled drug exposures including dulaglutide, 76% of symptomatic patients had vomiting.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableVomiting after pooled receptor agonist exposures
Study
n = 130
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Vomiting
76%
symptomatic patients; pooled exposures
Source sentences
Summary
Nausea (92%) and vomiting (76%) were the most reported clinical effects in the symptomatic group.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study of patients exposed to a GLP-1 or GLP-1/GIP RA across 3 poison centers between 2005 and 2023.
Summary · context
ToxSentryWeb identified 186 potential cases; 152 met the study criteria (130 symptomatic and 22 asymptomatic patients).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4026963503
08HumanNot a test of Semaglutide aloneObservational studySafety outcome
Among symptomatic patients after pooled GLP-1 or GLP-1/GIP agonist exposures including semaglutide, vomiting occurred in 76%.
In plain wordsAfter pooled drug exposures including semaglutide, 76% of symptomatic patients had vomiting.
Peptide
Semaglutide
Outcome
Not applicableVomiting after pooled receptor agonist exposures
Study
n = 130
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Vomiting
76%
symptomatic patients; pooled exposures
Source sentences
Summary
Nausea (92%) and vomiting (76%) were the most reported clinical effects in the symptomatic group.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study of patients exposed to a GLP-1 or GLP-1/GIP RA across 3 poison centers between 2005 and 2023.
Summary · context
ToxSentryWeb identified 186 potential cases; 152 met the study criteria (130 symptomatic and 22 asymptomatic patients).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4026963504
09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
After pooled GLP-1 or GLP-1/GIP agonist exposures including dulaglutide, most clinical effects lasted 8 to 24 hours.
In plain wordsAfter pooled drug exposures including dulaglutide, most clinical effects lasted 8 to 24 hours.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableDuration of clinical effects after pooled exposures
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Clinical effect duration
8 to 24 hours
most effects; pooled exposures
Source sentences
Summary
Most of the clinical effects lasted 8 to 24 hours.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study of patients exposed to a GLP-1 or GLP-1/GIP RA across 3 poison centers between 2005 and 2023.
Summary · context
ToxSentryWeb identified 186 potential cases; 152 met the study criteria (130 symptomatic and 22 asymptomatic patients).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4026963507
10HumanNot a test of Semaglutide aloneObservational studySafety outcome
After pooled GLP-1 or GLP-1/GIP agonist exposures including semaglutide, most clinical effects lasted 8 to 24 hours.
In plain wordsAfter pooled drug exposures including semaglutide, most clinical effects lasted 8 to 24 hours.
Peptide
Semaglutide
Outcome
Not applicableDuration of clinical effects after pooled exposures
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Clinical effect duration
8 to 24 hours
most effects; pooled exposures
Source sentences
Summary
Most of the clinical effects lasted 8 to 24 hours.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study of patients exposed to a GLP-1 or GLP-1/GIP RA across 3 poison centers between 2005 and 2023.
Summary · context
ToxSentryWeb identified 186 potential cases; 152 met the study criteria (130 symptomatic and 22 asymptomatic patients).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4026963508
11HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Clinical effects after pooled receptor agonist exposures including dulaglutide were managed with intravenous fluids in 56%.
In plain wordsAfter pooled drug exposures including dulaglutide, intravenous fluids managed clinical effects in 56%.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableIntravenous fluid management after pooled exposures
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Intravenous fluid use
56%
pooled exposures
Source sentences
Summary
These effects were managed primarily with intravenous fluids (56%) and/or antiemetics (51%).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study of patients exposed to a GLP-1 or GLP-1/GIP RA across 3 poison centers between 2005 and 2023.
Summary · context
ToxSentryWeb identified 186 potential cases; 152 met the study criteria (130 symptomatic and 22 asymptomatic patients).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4026963509
12HumanNot a test of Semaglutide aloneObservational studyOther
Clinical effects after pooled receptor agonist exposures including semaglutide were managed with intravenous fluids in 56%.
In plain wordsAfter pooled drug exposures including semaglutide, intravenous fluids managed clinical effects in 56%.
Peptide
Semaglutide
Outcome
Not applicableIntravenous fluid management after pooled exposures
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Intravenous fluid use
56%
pooled exposures
Source sentences
Summary
These effects were managed primarily with intravenous fluids (56%) and/or antiemetics (51%).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study of patients exposed to a GLP-1 or GLP-1/GIP RA across 3 poison centers between 2005 and 2023.
Summary · context
ToxSentryWeb identified 186 potential cases; 152 met the study criteria (130 symptomatic and 22 asymptomatic patients).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4026963510
13HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Clinical effects after pooled receptor agonist exposures including dulaglutide were managed with antiemetics in 51%.
In plain wordsAfter pooled drug exposures including dulaglutide, anti-nausea drugs managed clinical effects in 51%.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableAntiemetic management after pooled exposures
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Measurements
Antiemetic use
51%
pooled exposures
Source sentences
Summary
These effects were managed primarily with intravenous fluids (56%) and/or antiemetics (51%).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study of patients exposed to a GLP-1 or GLP-1/GIP RA across 3 poison centers between 2005 and 2023.
Summary · context
ToxSentryWeb identified 186 potential cases; 152 met the study criteria (130 symptomatic and 22 asymptomatic patients).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4026963511
14HumanNot a test of Semaglutide aloneObservational studyOther
Clinical effects after pooled receptor agonist exposures including semaglutide were managed with antiemetics in 51%.
In plain wordsAfter pooled drug exposures including semaglutide, anti-nausea drugs managed clinical effects in 51%.
Peptide
Semaglutide
Outcome
Not applicableAntiemetic management after pooled exposures
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Measurements
Antiemetic use
51%
pooled exposures
Source sentences
Summary
These effects were managed primarily with intravenous fluids (56%) and/or antiemetics (51%).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study of patients exposed to a GLP-1 or GLP-1/GIP RA across 3 poison centers between 2005 and 2023.
Summary · context
ToxSentryWeb identified 186 potential cases; 152 met the study criteria (130 symptomatic and 22 asymptomatic patients).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4026963512

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.